ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

• Status: Completed
• Trial end date: 2002-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Carboplatin; Pemetrexed

Criteria

Inclusion Criteria:

• You have a diagnosis of non-small cell lung cancer.

• You have received no prior chemotherapy.

• You have at least one measurable lesion.

• You have an adequate performance status.

• You are at least 18 years of age.

Exclusion Criteria:

• You have previously received chemotherapy for your lung cancer.

• You have received radiation within the last 30 days.

• You have active infection or other serious condition.

• You have brain metastasis.

• You have recently lost a significant amount of weight.